{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:00:15Z","timestamp":1773802815766,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-02886-6","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:27:08Z","timestamp":1770791228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel risk prediction model incorporating triglyceride-glucose-body mass index for in-hospital mortality in hypertensive patients with HFmrEF"],"prefix":"10.1186","volume":"25","author":[{"given":"Qilong","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huasheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TuEr-Hong","family":"Zukela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XingLi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baopeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","unstructured":"Mcdonagh TA, Metra M, Adamo M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and Chron Ic heart failure [J]. Eur Heart J, 42(36): 3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"issue":"11","key":"2886_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/ejhf.1629","volume":"21","author":"G Hao","year":"2019","unstructured":"Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012\u20132015. Eur J Heart Fail. 2019;21(11):1329\u201337. https:\/\/doi.org\/10.1002\/ejhf.1629.","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"2886_CR3","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","volume":"77","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Solomon SD. Classification of heart failure according to ejection fraction: JACC r eview topic of the week. J Am Coll Cardiol. 2021;77(25):3217\u201325. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.070.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2886_CR4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574\u201385. https:\/\/doi.org\/10.1002\/ejhf.813.","journal-title":"Eur J Heart Fail"},{"key":"2886_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.678121","volume":"8","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Li P, Zhao H, et al. Heart failure with mid-range ejection fraction: a distinctive subtype or a transitional stage? Front Cardiovasc Med. 2021;8:678121. https:\/\/doi.org\/10.3389\/fcvm.2021.678121.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"2886_CR6","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/cir.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93\u2013621. https:\/\/doi.org\/10.1161\/cir.0000000000001123.","journal-title":"Circulation"},{"issue":"8","key":"2886_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","volume":"5","author":"FH Messerli","year":"2017","unstructured":"Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017;5(8):543\u201351. https:\/\/doi.org\/10.1016\/j.jchf.2017.04.012.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2886_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01523-7","volume":"21","author":"J Su","year":"2022","unstructured":"Su J, Li Z, Huang M, et al. Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc Diabetol. 2022;21(1):96. https:\/\/doi.org\/10.1186\/s12933-022-01523-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2886_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02054-5","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Wu K, Lin Y, et al. Association of triglyceride glucose index with all-cause and cardiovascular mortality in the general population. Cardiovasc Diabetol. 2023;22(1):320. https:\/\/doi.org\/10.1186\/s12933-023-02054-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2886_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02045-9","volume":"23","author":"R Wang","year":"2024","unstructured":"Wang R, Chen C, Xu G, et al. Association of triglyceride glucose-body mass index and hemoglobin glycation index with heart failure prevalence in hypertensive populations: a study across different glucose metabolism status. Lipids Health Dis. 2024;23(1):53. https:\/\/doi.org\/10.1186\/s12944-024-02045-9.","journal-title":"Lipids Health Dis"},{"key":"2886_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2025.100416","volume":"41","author":"Y Liu","year":"2025","unstructured":"Liu Y, You H, Zhu Y. <article-title update=\"added\">Relationships of triglyceride\u2013glucose index and body mass index with 5-year all-cause mortality in patients with diabetes and comorbid hypertension: evidence from two prospective cohort studies. J Clin Transl Endocrinol. 2025;41:100416. https:\/\/doi.org\/10.1016\/j.jcte.2025.100416.","journal-title":"J Clin Transl Endocrinol"},{"issue":"12","key":"2886_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"7","key":"2886_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. <article-title update=\"added\">CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016;39(7):1108\u201314. https:\/\/doi.org\/10.2337\/dc16-0330.","journal-title":"Diabetes Care"},{"issue":"6","key":"2886_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers JG, Kamal FA, Robbins J. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118(6):1021\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306565.","journal-title":"Circ Res"},{"issue":"8","key":"2886_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","volume":"25","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America. J Card Fail. 2019;25(8):584\u2013619. https:\/\/doi.org\/10.1016\/j.cardfail.2019.05.007.","journal-title":"J Card Fail"},{"issue":"6","key":"2886_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.medin.2015.07.013","volume":"40","author":"J Jacob","year":"2016","unstructured":"Jacob J, Miro O, Herrero P. Predicci\u00f3n de la mortalidad a muy corto plazo de los pacientes con insuficiencia cardiaca cr\u00f3nica agudizada: escala EAHFE-3D. Med Intensiva. 2016;40(6):348\u201355. https:\/\/doi.org\/10.1016\/j.medin.2015.07.013.","journal-title":"Med Intensiva"},{"issue":"7","key":"2886_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41569-020-00504-1","volume":"18","author":"B Lopez","year":"2021","unstructured":"Lopez B, Ravassa S, Moreno MU. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol. 2021;18(7):479\u201398. https:\/\/doi.org\/10.1038\/s41569-020-00504-1.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2886_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol. 2013;62(4):263\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2886_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","volume":"5","author":"SM Dunlay","year":"2012","unstructured":"Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720\u20136. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.966366.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"2886_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese G, Vedin O, D\u2019amario D, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 2019;7(4):306\u201317. https:\/\/doi.org\/10.1016\/j.jchf.2018.11.019.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"2886_CR21","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/ejhf.879","volume":"19","author":"A Rastogi","year":"2017","unstructured":"Rastogi A, Novak E, Platts AE, et al. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1597\u2013605. https:\/\/doi.org\/10.1002\/ejhf.879.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2886_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.798","volume":"19","author":"P Rickenbacher","year":"2017","unstructured":"Rickenbacher P, Kaufmann BA, Maeder MT, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19(12):1586\u201396. https:\/\/doi.org\/10.1002\/ejhf.798.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2886_CR23","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jacc.2018.01.021","volume":"71","author":"JL Januzzi Jr.","year":"2018","unstructured":"Januzzi JL Jr., Chen-Tournoux AA, Christenson RH, et al. N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study. J Am Coll Cardiol. 2018;71(11):1191\u2013200. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.021.","journal-title":"J Am Coll Cardiol"},{"issue":"7492","key":"2886_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7492.625","volume":"330","author":"JA Doust","year":"2005","unstructured":"Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330(7492):625. https:\/\/doi.org\/10.1136\/bmj.330.7492.625.","journal-title":"BMJ"},{"issue":"5","key":"2886_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00392-016-1063-0","volume":"106","author":"D Farmakis","year":"2017","unstructured":"Farmakis D, Simitsis P, Bistola V, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol. 2017;106(5):359\u201368. https:\/\/doi.org\/10.1007\/s00392-016-1063-0.","journal-title":"Clin Res Cardiol"},{"issue":"12","key":"2886_CR26","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"Koh AS, Tay WT, Teng THK, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624\u201334. https:\/\/doi.org\/10.1002\/ejhf.945.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2886_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jchf.2017.04.007","volume":"5","author":"J Tromp","year":"2017","unstructured":"Tromp J, Khan M, Mentz RJ, et al. Biomarker profiles of acute heart failure patients with a mid-range ejection fraction. JACC: Heart Failure. 2017;5(7):507\u201317. https:\/\/doi.org\/10.1016\/j.jchf.2017.04.007.","journal-title":"JACC: Heart Failure"},{"issue":"4","key":"2886_CR28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/ehf2.12455","volume":"6","author":"NE Ibrahim","year":"2019","unstructured":"Ibrahim NE, Song Y, Cannon CP, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry(R) [J]. ESC Heart Fail. 2019;6(4):784\u201392. https:\/\/doi.org\/10.1002\/ehf2.12455.","journal-title":"ESC Heart Fail"},{"issue":"15","key":"2886_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1608664.","journal-title":"N Engl J Med"},{"issue":"6","key":"2886_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2459\/JCM.0000000000000653","volume":"19","author":"N Wang","year":"2018","unstructured":"Wang N, Hales S, Barin E, et al. Characteristics and outcome for heart failure patients with mid-range ejection fraction. J Cardiovasc Med (Hagerstown). 2018;19(6):297\u2013303. https:\/\/doi.org\/10.2459\/JCM.0000000000000653.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"12","key":"2886_CR31","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s00392-019-01477-z","volume":"108","author":"X Chen","year":"2019","unstructured":"Chen X, Savarese G, Dahlstrom U, et al. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. Clin Res Cardiol. 2019;108(12):1394\u2013405. https:\/\/doi.org\/10.1007\/s00392-019-01477-z.","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"2886_CR32","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230\u20139. https:\/\/doi.org\/10.1002\/ejhf.1149.","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"2886_CR33","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Mcmurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"issue":"9","key":"2886_CR34","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/ejhf.1797","volume":"22","author":"R Ferrari","year":"2020","unstructured":"Ferrari R, Fucili A, Rapezzi C. Understanding the results of the PARAGON-HF trial. Eur J Heart Fail. 2020;22(9):1531\u20135. https:\/\/doi.org\/10.1002\/ejhf.1797.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"2886_CR35","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/eurheartj\/ehaa731","volume":"41","author":"J Butler","year":"2020","unstructured":"Butler J, Zannad F, Filippatos G, et al. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. Eur Heart J. 2020;41(36):3398\u2013401. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa731.","journal-title":"Eur Heart J"},{"issue":"2","key":"2886_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"issue":"5","key":"2886_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455\u201362. https:\/\/doi.org\/10.1093\/eurheartj\/ehv464.","journal-title":"Eur Heart J"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02886-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02886-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02886-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:02:44Z","timestamp":1773795764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02886-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02886-6","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval number: K202403-48\u20132503\u00a0A-Y1). The requirement for informed consent was waived due to the retrospective nature of the analysis and the complete anonymization of all patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}